MANAGEMENT OF ENDOCRINE DISEASE: GH excess: diagnosis and medical therapy
Open Access
- 1 January 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 170 (1) , R31-R41
Abstract
Acromegaly is predominantly caused by a pituitary adenoma, which secretes an excess of GH resulting in increased IGF1 levels. Most of the GH assays used currently measure only the levels of the 22 kDa form of GH. In theory, the diagnostic sensitivity may be lower compared with the previous assays, which have used polyclonal antibodies. Many GH-secreting adenomas are plurihormonal and may co-secrete prolactin, TSH and α-subunit. Hyperprolactinaemia is found in 30–40% of patients with acromegaly, and hyperprolactinaemia may occasionally be diagnosed before acromegaly is apparent. Although trans-sphenoidal surgery of a GH-secreting adenoma remains the first treatment at most centres, the role of somatostatin analogues, octreotide long-acting repeatable and lanreotide Autogel as primary therapy is still the subject of some debate. Although the normalisation of GH and IGF1 levels is the main objective in all patients with acromegaly, GH and IGF1 levels may be discordant, especially during somatostatin analogue therapy. This discordance usually takes the form of high GH levels and an IGF1 level towards the upper limit of the normal range. Pasireotide, a new somatostatin analogue, may be more efficacious in some patients, but the drug has not yet been registered for acromegaly. Papers published on pasireotide have reported an increased risk of diabetes mellitus due to a reduction in insulin levels. Pegvisomant, the GH receptor antagonist, is indicated – alone or in combination with a somatostatin analogue – in most patients who fail to enter remission on a somatostatin analogue. Dopamine-D2-agonists may be effective as monotherapy in a few patients, but it may prove necessary to apply combination therapy involving a somatostatin analogue and/or pegvisomant.Keywords
This publication has 100 references indexed in Scilit:
- Preadipocytes proliferate and differentiate under the guidance of Delta-like 1 homolog (DLK1)Adipocyte, 2013
- Meta-Analysis on the Effects of Octreotide on Tumor Mass in AcromegalyPLOS ONE, 2012
- Mapping the growth hormone–Stat5b–IGF-I transcriptional circuitTrends in Endocrinology & Metabolism, 2012
- Novel mutations in MEN1, CDKN1B and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in SpainClinical Endocrinology, 2011
- Silencing of the Imprinted DLK1-MEG3 Locus in Human Clinically Nonfunctioning Pituitary AdenomasThe American Journal of Pathology, 2011
- Pituitary senescence: The evolving role of PttgMolecular and Cellular Endocrinology, 2010
- Basal, But Not Pulsatile, Growth Hormone Secretion Determines the Ambient Circulating Levels of Insulin-Like Growth Factor-IThe Journal of Clinical Endocrinology & Metabolism, 2010
- Bioactive Insulin-Like Growth Factor-I in ObesityThe Journal of Clinical Endocrinology & Metabolism, 2009
- Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic reviewPituitary, 2009
- Lower Visceral and Subcutaneous but Higher Intermuscular Adipose Tissue Depots in Patients with Growth Hormone and Insulin-Like Growth Factor I Excess Due to AcromegalyThe Journal of Clinical Endocrinology & Metabolism, 2008